Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Partners with Russian Investment Firm | Contract Pharma
Breaking News

Quintiles Partners with Russian Investment Firm

Will expand clinical development in Russia

Quintiles and Russian Venture Company Biofund, a Russian-based investment firm, have entered an agreement to support expansion of clinical development services in Russia.

The two companies will work to address Russia’s healthcare initiatives in accordance with its Healthcare 2020 Development Program. This will include implementing best practices to support medical science and the development of healthcare in line with international standards.

“With a population of almost 140 million, Russia is under-represented in terms of clinical development activity and over-represented in term of unmet medical needs,” said Ben Cons, global vice president, Quintiles Corporate Development. “Quintiles’ goal is to address both of those issues in partnership with RVC Biofund, which has experience in starting businesses in Russia and capital to invest in the biopharma sector.”

Egor Beketov, chief executive officer of RVC Biofund, said, “This partnership will help create high-technology services companies within the Russian Federation to advance biopharma, using RVC Biofund venture capital investments. With Quintiles, RVC Biofund gets a partner with the global resources and expertise to further expand development capabilities in Russia.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters